605 related articles for article (PubMed ID: 18467716)
41. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
42. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
[TBL] [Abstract][Full Text] [Related]
43. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.
Janssens A; Van Roy N; Poppe B; Noens L; Philippé J; Speleman F; Offner F
Eur J Haematol; 2012 Jul; 89(1):72-80. PubMed ID: 22509718
[TBL] [Abstract][Full Text] [Related]
44. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.
Sanchez-Carbayo M; Socci ND; Kirchoff T; Erill N; Offit K; Bochner BH; Cordon-Cardo C
Clin Cancer Res; 2007 Jun; 13(11):3215-20. PubMed ID: 17545525
[TBL] [Abstract][Full Text] [Related]
45. The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.
Hedström G; Thunberg U; Amini RM; Zainuddin N; Enblad G; Berglund M
Eur J Haematol; 2014 Dec; 93(6):500-8. PubMed ID: 24889555
[TBL] [Abstract][Full Text] [Related]
46. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
[TBL] [Abstract][Full Text] [Related]
47. Significance of zeta-associated protein (ZAP-70) and CD38 expression in chronic lymphocytic leukemia.
el-Sharnouby JA; el-Shakankiri AA; Hendy OM; Ahmed LM; Taha AM
Egypt J Immunol; 2006; 13(2):69-84. PubMed ID: 18689273
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.
Haferlach C; Dicker F; Schnittger S; Kern W; Haferlach T
Leukemia; 2007 Dec; 21(12):2442-51. PubMed ID: 17805327
[TBL] [Abstract][Full Text] [Related]
49. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia.
Buhl AM; Jurlander J; Geisler CH; Pedersen LB; Andersen MK; Josefsson P; Petersen JH; Leffers H
Eur J Haematol; 2006 Jun; 76(6):455-64. PubMed ID: 16529606
[TBL] [Abstract][Full Text] [Related]
50. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
[TBL] [Abstract][Full Text] [Related]
51. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
52. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
53. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
54. [Clonality analysis and mutation status of IgVH genes in classic Richter's syndrome].
Mao ZR; Rosenwald A; Zhang SJ; Zhou R; Mueller-Hermelink HK
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):364-70. PubMed ID: 19031714
[TBL] [Abstract][Full Text] [Related]
55. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
[TBL] [Abstract][Full Text] [Related]
56. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
57. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Kim SZ; Chow KU; Kukoc-Zivojnov N; Boehrer S; Brieger A; Steimle-Grauer SA; Harder L; Hoelzer D; Mitrou PS; Weidmann E
Leuk Lymphoma; 2004 Oct; 45(10):2037-45. PubMed ID: 15370248
[TBL] [Abstract][Full Text] [Related]
58. A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia.
Hassanein NM; Perkinson KR; Alcancia F; Goodman BK; Weinberg JB; Lagoo AS
Am J Clin Pathol; 2010 May; 133(5):708-17. PubMed ID: 20395517
[TBL] [Abstract][Full Text] [Related]
59. [Prognostic factors for chronic lymphocytic leukemia with typical and atypical immunophenotype].
Cao X; Xu W; Wu YJ; Qiao C; Liu Q; Fan L; Miao KR; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):450-3. PubMed ID: 19954596
[TBL] [Abstract][Full Text] [Related]
60. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
